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peptides, oligopeptides, small pep-
tides, and free amino acids (2).
Protein digestion is generally an
efficient system in which most of the
protein products of digestion found in
the portal vein are free amino acids.
However, numerous investigators
have reported detection, in the sys-
temic circulation, of small amounts of
dietary dipeptides, tripeptides, and
even minute amounts of protein frag-
ments and intact proteins, all from the
intestine. Gelatin has been shown to
increase the urinary excretion of the
dipeptide prolylhydroxyproline and
the tripeptide glycylprolyhydrox-
yproline of human volunteers (5). It
has even been reported that isolated
loops of adult rat small intestine,
which had been injected with insulin,
caused hypoglycemia, indicating that
it was absorbed in a biologically
active form (4).
It has been demonstrated that a soy
protein isolate, the Bowman Birk
protease inhibitor, becomes widely
distributed in the tissue of mice
following oral gavage. This inhibitor
was found in the liver, blood, lung,
kidney, and urine by using radioactive
techniques (5). Immunological tech-
niques have been used to quanti-
tatively measure p-lactoglobulin in
the serum of nonallergic healthy uni-
versity students after a "milk load"
(6). More extensive reviews are avail-
able on this subject (4,7,8).
Some of the components of shark
cartilage may similarly escape diges-
tion, enter the blood stream, and find
their way to a cancer site by the
blood circulation system. By this
mechanism, an orally ingested protein
could exert a biological effect on a
tumor outside the gastrointestinal
tract. Whether shark cartilage exerts a
biological effect on tumors by this
route of administration remains to be
demonstrated.
Skepticism is certainly warranted
on any new cancer therapy, but let us
not be too quick to dismiss anyone's
work.
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Sequential High-Dose
Combination Chemotherapy
With Granulocyte Colony-
Stimulating Factor and
Peripheral Blood Progenitor
Cells in Patients With Solid
Tumors: Intensification
Limited by Nonhematologic
Toxic Effects
In solid tumors, dose-intensive
treatments have often been given late
in the course of therapy by using a
single cycle of high-intensity
chemotherapy with the support of
autologous bone marrow transplanta-
tion (/). Relapses occur, however, in
the majority of patients, suggesting
the selection of resistant tumor clones.
Early delivery of multiple and sequen-
tial courses of high-dose combination
chemotherapy might produce superior
cell kill and decrease the emergence
of tumor-cell resistance (2). In recent
years, the use of hematopoietic
growth factors has reduced the dura-
tion of myelosuppression induced by
chemotherapy (3). These agents also
expand the pool of circulating pe-
ripheral blood progenitor cells that
can be harvested by leukapheresis and
reinfused following high-dose chemo-
therapy {4,5).
We designed a study in which re-
peated courses of high-dose combi-
nation chemotherapy were admin-
istered sequentially with the support
of peripheral blood progenitor cells
and granulocyte colony-stimulating
factor (G-CSF). Our purposes were
(a) to investigate whether G-CSF
alone could mobilize a sufficient
number of peripheral blood progenitor
cells for multiple treatment cycles and
(b) to define the limiting toxic effects
of such an approach. This study was
approved by the ethical committee of
our institution, and all the patients
gave written informed consent. Mobi-
lization of peripheral blood progenitor
cells was performed prior to chemo-
therapy by G-CSF (filgrastim) alone,
given subcutaneously at a dose of 12
u,g/kg per day for a median of 8 days
(range, 7-10 days). The median number
of leukaphereses was four (range, three
to five). This design allowed collection
of a median number of mononuclear
cells equal to 5.5 X lO^/kg (range,
3.6-19.9 X lOS/kg), which is equivalent
to 53.2 X lOVkg granulocyte-macro-
phage colony-forming units (GM-CFU)
(range, 41.4-210.1 X KrVkg) and 5.2 X
lfjfi/kg CD34-positive cells (range,
0.6-26.5 X lOfi/kg).
The chemotherapy program con-
sisted of 2500 mg/m2 cyclophos-
phamide on days 1 and 2; 300 mg/m2
etoposide on days 1, 2, and 3; and 50
mg/m2 cisplatin on days 1, 2, and 3.
This treatment program was to be re-
peated every 21 days for four cycles.
Mesna (4 g/m2 per day) was given as
a continuous intravenous infusion on
days 1 and 2. The projected average
dose intensity was 4.4 times higher
(6) than the standard regimen, which
is repeated every 21 days for six
cycles. Peripheral blood progenitor
cells were reinfused 24-48 hours after
the end of each chemotherapy cycle,
with G-CSF support at 12 y.g/kg per
day subcutaneously for 14 days or
less if early recovery occurred.
Between June 1992 and January
1993, seven patients were enrolled in
the study. Five patients had limited
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small-cell lung cancer (SCLC), one
had extensive SCLC, and one had
metastatic breast cancer. We were
able to evaluate 21 cycles of therapy.
Three patients completed the four
cycles that constituted full treatment;
two completed three cycles; one com-
pleted two cycles; and one completed
one cycle. The hematologic toxic
effects are summarized in Table 1.
Overall median times to recovery of
leukocyte recovery counts to at least
0.3, 0.5, or 1.0 X 109/L were 9, 10,
and 10 days, respectively. This period
was calculated from the day of peri-
pheral blood progenitor cell reinfu-
sion. The median time was 6 days
with a leukocyte count of 0.3 X 109/L
or less, 7 days with a leukocyte count
of 0.5 X 109/L or less, and 8 days
with a leukocyte count of 1.0 X 109/L
or less.
Thrombocytopenia did not last long
and did not cause clinically signifi-
cant bleeding. The median times to
recovery of platelet counts to 10 X
109/L or more and 20 X 109/L or
more were 10 and 11 days, respec-
tively; the median times with platelet
counts of 10 X 109/L or less and 20
X 109/L or less were 4 and 6 days,
respectively. The durations of neu-
tropenia and thrombocytopenia were
not significantly different between the
first and the fourth cycles. The
median number of GM-CFU/kg re-
infused after each cycle of chemo-
therapy was 6.6 X W/kg (range,
1.7-61.0 X ICH/kg). There was a
direct relationship between the num-
ber of reinfused GM-CFU and recov-
ery of bone marrow function. When
the number of GM-CFU was 10 X
\(y*/kg or less, the median time to
reach a leukocyte count of 1.0 X 109/
L or more was 11 days (range, 10-15
days). It was 9 days (range, 8-10
days) with a GM-CFU count of 10 X
lO-Vkg or more (P<.001). The median
time to platelet counts of 20 X 109/L
or more was 13 days (range, 9-15
days) after 10 X l(y*/kg or less GM-
CFU and 10 days (range, 9-12 days)
after more than 10 X lO^/kg reinfused
GM-CFU (/>>.O5).
The limiting toxic effects of this
treatment protocol were neurotoxic
effects and ototoxic effects after the
third and fourth treatment cycles. The
three patients who received four
cycles of treatment developed World
Health Organization (WHO) (7) grade
2 ototoxic effects and a median of
WHO grade 3 neurotoxic effects
(range, grades 2-3). These toxic
effects prompted us to cancel the
fourth cycle in subsequent patients.
The levels of leukocyte and platelet
counts would have allowed treatment
every 21 days, but a 1-week pause
was required in all patients who com-
plained of severe exhaustion. The
median weight loss was 3.5 kg (range,
2-8 kg) after one cycle and increased
Table 1. Hematologic toxic effects
to 8 kg (range, 7-11 kg) after the
fourth cycle. Other toxic effects con-
sisted of moderate nausea and vomit-
ing at the time of chemotherapy
administration and during the follow-
ing days. Mucositis and diarrhea were
mild except in two patients who
developed grade 3 esophagitis and in
one patient who had an episode of
transient ileus with bleeding. Among
the six patients with SCLC, four had
complete response and two had partial
response, according to WHO criteria
(7). The patient with metastatic breast
cancer obtained an unmaintained com-
plete remission lasting more than 12
months.
This correspondence describes the
feasibility of delivering multiple and
sequential courses of a combination
high-dose chemotherapy regimen with
G-CSF and peripheral blood progeni-
tor cell protection. However, the non-
hematologic toxic effects became the
dose-limiting toxic effects. Similar
findings were described when carbo-
platin alone was given in repeated
courses (8,9). The dose intensity of
our regimen was 62% of the projected
schedule, but it was 2.7 times higher
than that of a standard regimen. To
further increase dose intensity, the use
of agents that have mostly hemato-
logic toxic effects might be preferable
in the design of high-dose combi-
nation protocols, and treatments for
the protection of normal tissues
Median No. of days (range) to leukocyte recovery*
5»0.3 X 10"/L
S>0.5 X 109/L
s*1.0 X lffVL
Median No. of days (range) with leukocyte count
«0.3 X 1CP/L
•S0.5 X \QPfL
=Sl.O X 109/L
Median No. of days (range) to platelet recovery*
:*10 X 1CP/L
*20 X IffVL
Median No. of days (range) with platelet count
<C10 X 109/L
*20 X IO*/L
Median No. (range) of platelet transfusions
Median No. (range) of red blood cell transfusions
Median No. of days (range) of hospitalizalion
Median No. of days (range) with intravenous antibiotics
8
9
10
6
8
9
10
10
5
6
3.5
1
18
11
1
(8-11)
(9-14)
(9-15)
(5-9)
(6-12)
(7-13)
(7-14)
(9-15)
(1-10)
(1-11)
(1-9)
(0-4)
(15-44)
(6-14)
8.5
10
10
5.5
6.5
7.5
9
11
5
4
1.5
1.5
18
8
Cycle
2
(7-10)
(8-11)
(8-11)
(4-8)
(5-9)
(6-10)
(9-12)
(9-12)
(1-5)
(3-8)
(1-3)
(0-2)
(16-23)
(0-14)
No.
9
11
10
6
7
7
10
12
4
6.5
2
2
19
8
3
(8-10)
(8-12)
(9-12)
(6-7)
(5-9)
(6-9)
(7-11)
(10-14)
(1-5)
(6-9)
(2-3)
(1-3)
(15-20)
(0-14)
4
10 (9-11)
10 (9-11)
10 (10-12)
7 (6-8)
7 (6-9)
10 (8-11)
12 (9-12)
13 (9-14)
7 (1-7)
7 (2-9)
3 (1-4)
2 (2-4)
18 (18-20)
6 (0-8)
•Number of days calculated from day of reinfusion of peripheral blood progenitor cells.
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should also be developed (70).
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Selenium and DDE in Breast
Fat of Breast Cancer
Patients: Their Relationship
to Hormone Receptors in
Breast Tissue
In recent studies, higher concentra-
tions of neutral organochlorine DDE
(1,1 -dichloro-2,2-bis(p-chlorophenyl)
ethylene) and PCB (polychlorinated
biphenyls) have been found in breast
fat or serum of breast cancer patients
than in control subjects (1-3). We
have also investigated the occurrence
of certain neutral organochlorine com-
pounds and antioxidants (selenium
[Se], copper [Cu], and zinc [Zn]).
Only residues of pJ-hexachloro-
cyclohexane were significantly more
frequent in cancer patients than in
controls (P = .03) (4). When parity
and age were adjusted for, the odds
ratio was 10.51 (95% confidence in-
terval [CI] = 2.00-55.26) for patients
whose breast adipose tissue had
3-hexachlorocyclohexane of more
than 0.1 mg/kg fat.
In rat and mouse studies, Se has
had an inhibiting effect on car-
cinogen-induced and spontaneous
mammary gland cancer (5-7). Inhibi-
tion of mammary tumorigenesis re-
quires the continuous presence of Se.
After withdrawal of the Se supple-
ment, mammary tumorigenesis reap-
pears at the same rate as tumors in
the control mice and rats (8). In
breast cancer patients, however, the
finding of lower levels of Se in serum
has not been consistent (9).
We (70) found that the mean Se
concentration in the breast tissue of
cancer patients was nearly statistically
significantly higher than in the breast
tissue of healthy controls (P = .06).
This finding is in accordance with a
mouse study by Lane and Medina (7)
suggesting that breast cancer tissue
may concentrate Se.
Here, we report our results on the
relationship of Se, Cu, and Zn and
certain organochlorine compounds to
the amount of estrogen receptors
(ERs) and progesterone receptors
(PRs) found in the cancer tissue
(Table 1). The study material con-
sisted of adipose samples of breast
tissue of 44 breast cancer patients
aged 34-82 years (mean, 56 years; SD
± 11 years) who were residents of
the Helsinki area [reported in detail
(4,70)]. Of these carcinomas, 76%
were ductal. Stage of the disease was
recorded using the UICC system of
staging (77). Organochlorine con-
centrations were detected by mass
spectrometry and concentrations of
antioxidants by atomic absorption.
The ER and PR levels were measured
in 30 patients by the method reported
by Vihko et al. (72).
A positive correlation was found
between Se (n-g/kg breast tissue) and
ER (fmol/mg cytosol protein) (rs =
.480; 95% CI = .14-.72; P = .007).
When patients whose disease was
classified as stage IV (i.e., distant
metastases) were omitted (three
cases), a positive correlation was
found between DDE and ER concen-
trations (r5 = .490; 95% CI = .14-.74;
P = .009). B-Hexachlorocyclohexane
had no association with ER, in
accordance with in vitro studies by
Coosen and van Velsen (75).
Our results suggest that Se may act
via ER. The positive association of
DDE with ER may indicate that the
carcinogenic effect of DDE is indirect
and may also be associated with ER.
This connection between ER and pol-
lutants like DDE may also explain the
recent increase in ER-positive breast
cancers compared with ER-negative
breast cancers (14).
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